BioNTech Results Presentation Deck

1 BNT111 Fixvac Melanoma: Planning to initiate randomized phase 2 trial 10 Ongoing Phase 1 trial in Advanced Melanoma published in Nature Regeneron strategic collaboration and planned Phase 2 trial ● ● ● Phase 1 trial data in CPI-experienced patients in monotherapy and in combination with anti-PD1 previously reported in July 2020 and published in Nature All patients showed tumor associated antigen (TAA) specific T cell responses with In vitro stimulation, and > 75% of patients showed immune responses against ≥ 1 TAA on an ex vivo basis - T cells responses ramped up over 4-8 weeks and increased or remained stable up to over one year with monthly maintenance therapy. Reported durable clinical responses in monotherapy and in combination with anti-PD1 accompanied by high magnitude CD4+ and CD8+ response Signed strategic collaboration to jointly conduct randomized Phase 2 trial with BNT111 and Libtayo® (cemiplim ab anti-PD-1 therapy) Targeting patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma Companies to share development costs equally and keep full commercial rights to own programs Plan to initiate potentially registrational Phase 2 trial by the end of 2020 - more details on anticipated trial design to be released in Q3 BIONTECH

View entire presentation